Yazar "Yilmaz, U." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Central giant cell lessions (CGCL) of the jaws in children - The review of 34 cases
    (Taylor & Francis Ltd, 2007) Tamrikulu, R.; Erol, B.; Yilmaz, U.; Yaman, F.; Atilgan, S.
    The aim of this study was to evaluate CGCL in children in regard with age and gender of patients, and location and site of lessions. The study was conducted on 29 cases of CGCG, 4 cases of CGT and one cherubism, which were recovered from the archives of our department by searching the files from 1988 to 2005 for the age group ranging from 4 to 15 years of age. The ratios of the variables under question (occurence, gender location and site) to total cases (percentages), mathematical averages and the statistical comparison of age distribution were used for estimations as the methods of the study. The percentage of CGCL in male 68% is significantly higher than that of female 38%, whereas the occurence of the lessions in mandibula 68% is greater than that of maxilla 29%. Also, the occurence of the tumors in anterior position 57% is higher than that in all the other positions 43%. No significant difference was found among groups for the age distribution. The present data indicates a male predilection and a preponderance of anterior position of mandibula for the studied age group.
  • [ X ]
    Öğe
    An experimental comparison of the effects of calcium sulfate particles and ?-tricalcium phosphate/hydroxyapatite granules on osteogenesis in internal bone cavities
    (Taylor & Francis Ltd, 2007) Atilgan, S.; Yaman, F.; Yilmaz, U.; Gorgun, B.; Unlu, G.
    This experimental study was carried out to investigate the effect of medical grade calcium sulphate and beta-tricalcium phosphate/hydroxyapatite on new bone formation. Additionally, the study compared these materials for infection, resorption, biocompatibility, immune reaction, fibrotic encapsulation, foreign body reaction and physical attachment. Forty, five-month-old female Wistar Albino rats were used. The 40 rats in the study were divided into 2 groups. Medical grade calcium sulphate particles (SurgiPlaster(R), Bio-Lok International Company) were applied to the rats in group 1 and beta-tricalcium phosphate/hydroxyapatite granules (Camceram(R) Cam Implants by an osteotech, Inc. Company) to those in group 2. On days 10, 21, 30 and 60 postoperatively the femurs were sacrificed and investigated histopathologically. The Mann-Whitney U test was applied to the data obtained as a result of the histopathological analysis of the specimens. No statistically significant differences were observed between the 2 groups. In conclusion, it was determined that both materials resulted in similar fibrous tissue and inflammation responses, that their biocompatibilities were very good and that they did not cause foreign body reaction. Osteogenesis also was observed in the 2 groups after day 21. The effects of calcium sulphate on bone formation were faster than those of beta-tricalcium phosphate/hydroxyapatite. Osteogenesis was not completed to the same extent in the calcium sulphate group as in the beta-tricalcium phosphate/hydroxyapatite group.
  • [ X ]
    Öğe
    Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure
    (Zerbinis Medical Publ, 2011) Alkis, N.; Demirci, U.; Benekli, M.; Yilmaz, U.; Isikdogan, A.; Sevinc, A.; Ozdemir, N. Y.
    Purpose: To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients. Methods: All patients in this study had previously failed oxaliplatin and irinotecan-based chemotherapy. Patients were treated with MMC (6 mg/m(2) intravenously/i.v) on day 1 in combination with either oral UFT (500 mg/m(2)) and oral leucovorin (LV) (30 mg) on days 1-14 every 3 weeks (group A) or infusional 5-fluorouracil (5-FU) by deGramont regimen with i.v. LV (200 mg/m(2)) on days I and 2, every 2 weeks (group B). Results: Thirty-nine MCRC patients were analyzed. Twenty-two of them were in group A and 17 in group B. Thirty-three were evaluable for clinical efficacy The clinical benefit in the intent-to-treat (ITT) population was 30.8%. Median progression free survival (PFS) was 6 months (95% confidence interval/CI 4-8) and median overall survival (OS) 9 months (95% CI 6.5-11.5). Median PFS was 3 months (95% CI 2.4-3.6) in group A and 7 months (95% CI 5.1-8.9) in group B (p=0.009). Median OS was 7 months (95% CI 4.3-9.7) in group A and 12 months (95% CI 5.4-18.6) in group B (p=0.422). The combination of MMC and fluoropyrimidines was generally well tolerated. The most common severe toxicities were nausea and vomiting, neutropenia, hepatotoxicity and diarrhea. Conclusion: MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients. This combination remains a viable option in these patients. However better therapies are urgently needed.